|Full Name:||Tamoxifen Test|
The following information provides a overview of the Tamoxifen Test test.
Tamoxifen is a medication given to patients for the treatment of different types of breast cancer. The Tamoxifen Test is a specific test for the genetics status for Tamoxifen treatment to assist in minimising the risk of tamoxifen treatment failure.
A recent article published in the Journal of American Medical Association highlighted the importance of having a pharmacogenomic testing of CYP2D6 gene prior to tamoxifen treatments.
The study aimed to determine whether CYP2D6 genetic status are associated with clinical outcomes in these women receiving the treatments.
1,325 people participated in the study and upon 9 years follow-up, the study found that the recurrence risk of breast cancer is:
14.9% in individuals who are extensive metabolisers of CYP2D6
20.9% in individuals who are intermediate metabolisers of CYP2D6
29.0% in individuals who are poor metabolisers of CYP2D6
This study clearly demonstrates that knowing your genetic status prior to tamoxifen treatment will benefit patients, minimising the risk of tamoxifen treatment failure and improving the overall outcome.
For the complete abstract of the article, please follow this link:
|How to get:||View Ordering Information|
|Schroth W, Goetz MP, Hamann U, et al. (2009)||Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009 Oct 7;302(13):1429-36.|